• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Palisade Bio, Inc. - Common Stock (NQ:PALI)

1.640 -0.050 (-2.96%)
Streaming Delayed Price Updated: 12:21 PM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Palisade Bio, Inc. - Common Stock

News headline image
Power Metallic (TSXV: PNPN | OTCQB: PNPNF) Eyes NYSE Uplisting as Polymetallic Discoveries Accelerate – More Stocks Inside
October 01, 2025
Via AB Newswire
News headline image
Loop Industries (NASDAQ: LOOP) Builds Global Momentum in Circular Textiles w/ Twist™ – More Stocks Inside
August 07, 2025
Via AB Newswire
News headline image
JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now Live
July 22, 2025
Via ACCESS Newswire
News headline image
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
January 11, 2023
Via ACCESSWIRE
News headline image
Palisade Bio Announces Early Exercise of Warrants Resulting in Cash Proceeds of $1.25 Million
December 07, 2022
From Palisade Bio, Inc.
Via GlobeNewswire
News headline image
Palisade Bio Regains Compliance with Nasdaq Listing Requirements
December 01, 2022
From Palisade Bio, Inc.
Via GlobeNewswire
News headline image
Palisade Bio (NASDAQ: PALI) Awarded Fast Track Designation from U.S. FDA for LB1148
November 22, 2022
Palisade Bio, Inc. (NASDAQ: PALI) is engaged as a biopharmaceutical company, which is focused on the research and development of 
Via Spotlight Growth
News headline image
Palisade Bio is Granted Fast Track Designation from the U.S. Food and Drug Administration for LB1148 for Accelerated Return of Bowel Function following GI Surgery
November 22, 2022
From Palisade Bio, Inc.
Via GlobeNewswire
News headline image
Palisade Bio Appoints Herbert B. Slade, MD, FAAAAI as Chief Medical Officer
November 18, 2022
From Palisade Bio, Inc.
Via GlobeNewswire
News headline image
Palisade Bio Releases In-Depth Explanation of Scientific Approach of Lead Product Candidate LB1148 Through Animated Video
November 17, 2022
From Palisade Bio, Inc.
Via GlobeNewswire
News headline image
Palisade Bio Announces Reverse Stock Split
November 15, 2022
From Palisade Bio, Inc.
Via GlobeNewswire
News headline image
Palisade Bio Reports Third Quarter 2022 Financial Results and Provides Business Update
November 14, 2022
From Palisade Bio, Inc.
Via GlobeNewswire
News headline image
Palisade Bio Announces Executive Leadership Transition
October 11, 2022
From Palisade Bio, Inc.
Via GlobeNewswire
News headline image
Palisade Bio Announces Oral Presentation of Phase 2 Data at the American College of Surgeons (ACS) Clinical Congress 2022
September 29, 2022
From Palisade Bio, Inc.
Via GlobeNewswire
News headline image
Preventing Post-Surgical Abdominal Adhesions: Virtual Presentation on Palisade Bio's LB1148 Clinical Data; To Be Hosted & Moderated by Stonegate Capital Partners
March 14, 2022
Dallas, Texas--(Newsfile Corp. - March 14, 2022) - Stonegate Capital Partners is hosting a... 
Via Newsfile
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap